Download MendeleySynthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz, R.P., Liu, L., Yang, K., Nishimura, N., Bo, Y., Pettus, L.H., Caenepeel, S., Freeman, D.J., McCarter, J.D., Mullady, E.L., Miguel, T.S., Wang, L., Zhang, N., Andrews, K.L., Whittington, D.A., Jiang, J., Subramanian, R., Hughes, P.E., Norman, M.H.(2012) Bioorg Med Chem Lett 22: 5714-5720
- PubMed: 22832322 Search on PubMed
- DOI: https://doi.org/10.1016/j.bmcl.2012.06.078
- Primary Citation Related Structures:
4F1S - PubMed Abstract:
Phosphoinositide 3-kinase (PI3K) is an important target in oncology due to the deregulation of the PI3K/Akt signaling pathway in a wide variety of tumors. A series of 4-amino-6-methyl-1,3,5-triazine sulfonamides were synthesized and evaluated as inhibitors of PI3K. The synthesis, in vitro biological activities, pharmacokinetic and in vivo pharmacodynamic profiling of these compounds are described. The most promising compound from this investigation (compound 3j) was found to be a pan class I PI3K inhibitor with a moderate (>10-fold) selectivity over the mammalian target of rapamycin (mTOR) in the enzyme assay. In a U87 MG cellular assay measuring phosphorylation of Akt, compound 3j displayed low double digit nanomolar IC(50) and exhibited good oral bioavailability in rats (F(oral)=63%). Compound 3j also showed a dose dependent reduction in the phosphorylation of Akt in a U87 tumor pharmacodynamic model with a plasma EC(50)=193 nM (91 ng/mL).
- Department of Chemistry Research & Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. rwurz@amgen.com
Organizational Affiliation:
